Compare
Guardant Health, Inc. vs Caris Life Sciences, Inc. vs Veracyte, Inc. vs Natera, Inc.
| Latest fiscal year | Guardant Health, Inc. GH | Caris Life Sciences, Inc. CAI | Veracyte, Inc. VCYT | Natera, Inc. NTRA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $982.02M | $812.03M | $517.14M | $2.31B |
| Revenue growth (YoY) | +32.9% | +97.0% | +16.0% | +35.9% |
| Gross margin | 64.5% (computed) | n/a | 70.1% | n/a |
| Operating margin | -44.5% | 5.6% | 11.2% | -13.4% |
| Net margin | -42.4% | -8.4% | 12.8% | -9.0% |
| Net income | -$416.28M | -$68.09M | $66.35M | -$208.16M |
| EPS (Diluted) | -$3.32 | -$3.22 | $0.82 | -$1.52 |
| Operating cash flow | -$184.76M | $83.16M | $136.31M | $215.30M |
| Free cash flow | -$233.07M | $66.89M | $126.63M | $109.11M |
| Cash & equivalents | $378.20M | $796.27M | $362.58M | n/a |
| Total assets | $2.01B | $1.13B | $1.41B | $2.40B |
| Total liabilities | $2.11B | $548.36M | $96.44M | $685.93M |
| Shareholders' equity | -$99.31M | $577.31M | $1.31B | $1.71B |
| Return on year-end equity | n/a | -11.8% | 5.1% | -12.2% |
| Shares outstanding | 130.64M | 282.53M | 79.36M | 139.69M |
Revenue, most recent five fiscal years
| Fiscal year | Guardant Health, Inc. | Caris Life Sciences, Inc. | Veracyte, Inc. | Natera, Inc. |
|---|---|---|---|---|
| Latest | $982.02M Ended 2025-12-31 | $812.03M Ended 2025-12-31 | $517.14M Ended 2025-12-31 | $2.31B Ended 2025-12-31 |
| 1 year earlier | $739.02M Ended 2024-12-31 | $412.26M Ended 2024-12-31 | $445.76M Ended 2024-12-31 | $1.70B Ended 2024-12-31 |
| 2 years earlier | $563.95M Ended 2023-12-31 | $306.13M Ended 2023-12-31 | $361.05M Ended 2023-12-31 | $1.08B Ended 2023-12-31 |
| 3 years earlier | $449.54M Ended 2022-12-31 | n/a | $296.54M Ended 2022-12-31 | $820.22M Ended 2022-12-31 |
| 4 years earlier | $373.65M Ended 2021-12-31 | n/a | $219.51M Ended 2021-12-31 | $625.49M Ended 2021-12-31 |